{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:54:46Z","timestamp":1790139286831,"version":"4.0.1"},"reference-count":99,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.urolonc.2016.10.009","type":"journal-article","created":{"date-parts":[[2016,11,9]],"date-time":"2016-11-09T11:00:22Z","timestamp":1478689222000},"page":"21-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["A review for clinicians: Prostate cancer and the antineoplastic properties of metformin"],"prefix":"10.1016","volume":"35","author":[{"given":"Stephen J.","family":"Hankinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Fam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin N.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2016.10.009_bib1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.18632\/oncotarget.387","article-title":"Metformin: multi-faceted protection against cancer","volume":"2","author":"Del Barco","year":"2011","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2016.10.009_bib2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1749-6632.2010.05679.x","article-title":"Metformin in polycystic ovary syndrome","volume":"1205","author":"Diamanti-Kandarakis","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.urolonc.2016.10.009_bib3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.2007.56-b","article-title":"Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial","volume":"299","author":"Wu","year":"2008","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.urolonc.2016.10.009_bib4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1586\/14779072.5.3.491","article-title":"Treating the metabolic syndrome","volume":"5","author":"Bianchi","year":"2007","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.urolonc.2016.10.009_bib5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2016.10.009_bib6","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/JME-12-0007","article-title":"Metformin in cancer: translational challenges","volume":"48","author":"Dowling","year":"2012","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.urolonc.2016.10.009_bib7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2004.12.003","article-title":"AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism","volume":"1","author":"Kahn","year":"2005","journal-title":"Cell Metab"},{"key":"10.1016\/j.urolonc.2016.10.009_bib8","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.2337\/diabetes.53.4.1052","article-title":"Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?","volume":"53","author":"Brunmair","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.urolonc.2016.10.009_bib9","doi-asserted-by":"crossref","first-page":"10269","DOI":"10.1158\/0008-5472.CAN-06-1500","article-title":"Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells","volume":"66","author":"Zakikhani","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2016.10.009_bib10","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/1940-6207.CAPR-13-0337","article-title":"Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment","volume":"7","author":"Yue","year":"2014","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.urolonc.2016.10.009_bib11","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1158\/0008-5472.CAN-07-2310","article-title":"Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells","volume":"67","author":"Dowling","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2016.10.009_bib12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bbrc.2004.06.133","article-title":"AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms","volume":"321","author":"Xiang","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.urolonc.2016.10.009_bib13","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/emmm.201302734","article-title":"A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis","volume":"6","author":"Zadra","year":"2014","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.urolonc.2016.10.009_bib14","doi-asserted-by":"crossref","first-page":"15652","DOI":"10.18632\/oncotarget.3404","article-title":"Metformin-induced energy deficiency leads to the inhibition of lipogenesis in prostate cancer cells","volume":"6","author":"Loubi\u00e8re","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2016.10.009_bib15","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1172\/JCI40671","article-title":"Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1\/AMPK pathway via a decrease in hepatic energy state","volume":"120","author":"Foretz","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.urolonc.2016.10.009_bib16","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1172\/JCI43661","article-title":"An energetic tale of AMPK-independent effects of metformin","volume":"120","author":"Miller","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.urolonc.2016.10.009_bib17","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nature11808","article-title":"Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP","volume":"494","author":"Miller","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2016.10.009_bib18","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.cmet.2010.03.014","article-title":"Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner","volume":"11","author":"Kalender","year":"2010","journal-title":"Cell Metab"},{"key":"10.1016\/j.urolonc.2016.10.009_bib19","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1158\/0008-5472.CAN-10-1769","article-title":"Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1","volume":"71","author":"Ben Sahra","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2016.10.009_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms1859","article-title":"Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC","volume":"3","author":"Blandino","year":"2012","journal-title":"Nat Commun"},{"key":"10.1016\/j.urolonc.2016.10.009_bib21","doi-asserted-by":"crossref","first-page":"765","DOI":"10.7314\/APJCP.2013.14.2.765","article-title":"Therapeutic potential of an anti-diabetic drug, metformin: alteration of miRNA expression in prostate cancer cells","volume":"14","author":"Avci","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.urolonc.2016.10.009_bib22","first-page":"1","article-title":"Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1","volume":"18","author":"Zhuang","year":"2008","journal-title":"J Mol Signal 3"},{"key":"10.1016\/j.urolonc.2016.10.009_bib23","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1093\/carcin\/bgt307","article-title":"Metformin targets c-MYC oncogene to prevent prostate cancer","volume":"34","author":"Akinyeke","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.urolonc.2016.10.009_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/oncsis.2015.18","article-title":"Metformin induces ER stress-dependent apoptosis through miR-708-5p\/NNAT pathway in prostate cancer","volume":"4","author":"Yang","year":"2015","journal-title":"Oncogenesis"},{"key":"10.1016\/j.urolonc.2016.10.009_bib25","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/1535-7163.MCT-14-0102","article-title":"Inhibition of the GTPase Rac1 mediates the antimigratory effects of metformin in prostate cancer cells","volume":"14","author":"Dirat","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.urolonc.2016.10.009_bib26","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1055\/s-0042-100910","article-title":"Diabetes and cancer: a review of current knowledge","volume":"124","author":"Wojciechowska","year":"2016","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.urolonc.2016.10.009_bib27","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/bies.20151","article-title":"Insulin and its receptor: structure, function and evolution","volume":"26","author":"De Meyts","year":"2004","journal-title":"Bioessays"},{"key":"10.1016\/j.urolonc.2016.10.009_bib28","doi-asserted-by":"crossref","first-page":"F9","DOI":"10.1530\/ERC-12-0105","article-title":"Diabetes and pancreatic cancer","volume":"19","author":"Cui","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.urolonc.2016.10.009_bib29","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/CCO.0b013e328356da72","article-title":"Glucose transporters in cancer metabolism","volume":"24","author":"Adekola","year":"2012","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.urolonc.2016.10.009_bib30","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.urolonc.2016.10.009_bib31","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nrc3967","article-title":"Adiposity and cancer risk: new mechanistic insights from epidemiology","volume":"15","author":"Renehan","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.urolonc.2016.10.009_bib32","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nrc2536","article-title":"Insulin and insulin-like growth factor signalling in neoplasia","volume":"8","author":"Pollak","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.urolonc.2016.10.009_bib33","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.tem.2006.08.006","article-title":"Obesity and cancer risk: the role of the insulin-IGF axis","volume":"17","author":"Renehan","year":"2006","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.urolonc.2016.10.009_bib34","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ghir.2007.01.004","article-title":"Role of the integrin \u03b1V\u03b23 in mediating increased smooth muscle cell responsiveness to IGF-I in response to hyperglycemic stress","volume":"17","author":"Clemmons","year":"2007","journal-title":"Growth Horm IGF Res"},{"key":"10.1016\/j.urolonc.2016.10.009_bib35","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1158\/0008-5472.CAN-06-1712","article-title":"Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin","volume":"67","author":"Zhang","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2016.10.009_bib36","doi-asserted-by":"crossref","first-page":"6539","DOI":"10.1158\/0008-5472.CAN-09-0418","article-title":"Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth","volume":"69","author":"Kisfalvi","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2016.10.009_bib37","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1530\/REP-09-0351","article-title":"Metformin decreases IGF1-induced cell proliferation and protein synthesis through AMP-activated protein kinase in cultured bovine granulosa cells","volume":"139","author":"Tosca","year":"2010","journal-title":"Reproduction"},{"key":"10.1016\/j.urolonc.2016.10.009_bib38","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bbrc.2015.03.178","article-title":"Metformin inhibits the proliferation of human prostate cancer PC-3 cells via the downregulation of insulin-like growth factor 1 receptor","volume":"461","author":"Kato","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.urolonc.2016.10.009_bib39","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00280-016-3037-3","article-title":"Combinational strategies of metformin and chemotherapy in cancers","volume":"78","author":"Zhang","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.urolonc.2016.10.009_bib40","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2337\/dc14-1996","article-title":"Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations, detection bias, and reverse causation","volume":"38","author":"Harding","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.urolonc.2016.10.009_bib41","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/ijc.28989","article-title":"Diabetes mellitus and risk of prostate cancer in the European prospective investigation into cancer and nutrition","volume":"136","author":"Tsilidis","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2016.10.009_bib42","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/pcan.2012.40","article-title":"Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies","volume":"16","author":"Bansal","year":"2013","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urolonc.2016.10.009_bib43","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.eururo.2014.01.040","article-title":"Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort","volume":"67","author":"Bhindi","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.10.009_bib44","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.clgc.2014.01.001","article-title":"Type 2 diabetes: a protective factor for prostate cancer? An overview of proposed mechanisms","volume":"12","author":"Rastmanesh","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2016.10.009_bib45","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.eururo.2012.11.013","article-title":"Obesity and prostate cancer: weighing the evidence","volume":"63","author":"Allott","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.10.009_bib46","first-page":"329","article-title":"Type 2 diabetes and the risk of mortality among patients with prostate cancer","volume":"25","author":"Bensimon","year":"2014","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.urolonc.2016.10.009_bib47","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","article-title":"Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth","volume":"68","author":"Montgomery","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2016.10.009_bib48","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/pros.21445","article-title":"Altered prostate epithelial development in mice lacking the androgen receptor in stromal fibroblasts","volume":"72","author":"Yu","year":"2012","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2016.10.009_bib49","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/pros.10327","article-title":"Regulation of rat prostate stromal cell myodifferentiation by androgen and TGF-\u03b2 1","volume":"58","author":"Gerdes","year":"2004","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2016.10.009_bib50","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1158\/2159-8290.CD-12-0460","article-title":"Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer","volume":"3","author":"Logothetis","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.urolonc.2016.10.009_bib51","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1038\/sj.onc.1211024","article-title":"The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level","volume":"27","author":"Ben Sahra","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.urolonc.2016.10.009_bib52","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/sj.bjc.6603615","article-title":"Impact of differential cyclin D1 expression and localisation in prostate cancer","volume":"96","author":"Comstock","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2016.10.009_bib53","doi-asserted-by":"crossref","first-page":"7783","DOI":"10.1158\/0008-5472.CAN-05-4472","article-title":"Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins","volume":"66","author":"Xu","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2016.10.009_bib54","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1101\/gad.1256504","article-title":"Living with or without cyclins and cyclin-dependent kinases","volume":"18","author":"Sherr","year":"2004","journal-title":"Genes Dev"},{"key":"10.1016\/j.urolonc.2016.10.009_bib55","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1101\/gad.854900","article-title":"Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation","volume":"14","author":"Alt","year":"2000","journal-title":"Genes Dev"},{"key":"10.1016\/j.urolonc.2016.10.009_bib56","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.3892\/or.2013.2718","article-title":"Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1\/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo","volume":"30","author":"Cai","year":"2013","journal-title":"Oncol Rep"},{"key":"10.1016\/j.urolonc.2016.10.009_bib57","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.canlet.2014.09.001","article-title":"SMILE upregulated by metformin inhibits the function of androgen receptor in prostate cancer cells","volume":"354","author":"Lee","year":"2014","journal-title":"Cancer Lett"},{"key":"10.1016\/j.urolonc.2016.10.009_bib58","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1210\/en.2013-1925","article-title":"Metformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling","volume":"155","author":"Malaguarnera","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.urolonc.2016.10.009_bib59","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/pros.23000","article-title":"Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor","volume":"75","author":"Wang","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2016.10.009_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep15639","article-title":"Metformin attenuates testosterone-induced prostatic hyperplasia in rats: a pharmacological perspective","volume":"5","author":"Mosli","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2016.10.009_bib61","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.eururo.2014.04.027","article-title":"Metformin use and prostate cancer risk","volume":"66","author":"Preston","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.10.009_bib62","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1016\/j.ejca.2014.08.007","article-title":"Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus","volume":"50","author":"Tseng","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2016.10.009_bib63","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1158\/1055-9965.EPI-10-0940","article-title":"Metformin and the incidence of prostate cancer in patients with type 2 diabetes","volume":"20","author":"Azoulay","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.urolonc.2016.10.009_bib64","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/pds.3823","article-title":"No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK","volume":"24","author":"Kowall","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.urolonc.2016.10.009_bib65","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ejca.2015.02.003","article-title":"The risk of prostate cancer for men on aspirin, statin or antidiabetic medications","volume":"51","author":"Nordstrom","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2016.10.009_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0071583","article-title":"Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review","volume":"8","author":"Franciosi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2016.10.009_bib67","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.canep.2012.12.009","article-title":"Association of metformin use with cancer incidence and mortality: a meta-analysis","volume":"37","author":"Zhang","year":"2013","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.urolonc.2016.10.009_bib68","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/amiajnl-2014-002649","article-title":"Validating drug repurposing signals using electron health records: a case study of metformin associated with reduced cancer mortality","volume":"22","author":"Xu","year":"2015","journal-title":"J Am Med Inform Assoc"},{"key":"10.1016\/j.urolonc.2016.10.009_bib69","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2012.46.7043","article-title":"Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes","volume":"31","author":"Margel","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.10.009_bib70","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00345-013-1171-7","article-title":"Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer","volume":"32","author":"Rieken","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2016.10.009_bib71","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1158\/1940-6207.CAPR-15-0141","article-title":"Metformin use and risk of prostate cancer: results from the REDUCE study","volume":"8","author":"Feng","year":"2015","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.urolonc.2016.10.009_bib72","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/pcan.2014.52","article-title":"Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis","volume":"18","author":"Raval","year":"2015","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urolonc.2016.10.009_bib73","doi-asserted-by":"crossref","first-page":"595","DOI":"10.7314\/APJCP.2015.16.2.595","article-title":"Metformin association with lower prostate cancer recurrence in type 2 diabetes: a systematic review and meta-analysis","volume":"16","author":"Hwang","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.urolonc.2016.10.009_bib74","first-page":"105","article-title":"Metformin and prostate cancer mortality: a meta-analysis","volume":"27","author":"Stopsack","year":"2016","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.urolonc.2016.10.009_bib75","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/pcan.2015.35","article-title":"Metformin and prostate cancer stem cells: a novel therapeutic target","volume":"18","author":"Mayer","year":"2015","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urolonc.2016.10.009_bib76","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.tem.2016.02.006","article-title":"Diabetes mellitus type 2: a driving force for urological complications","volume":"27","author":"Sayyid","year":"2016","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.urolonc.2016.10.009_bib77","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1158\/1940-6207.CAPR-15-0014","article-title":"Effect of metformin, rapamycin, and their combination on growth and progression of prostate tumors in HiMyc mice","volume":"8","author":"Saha","year":"2015","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.urolonc.2016.10.009_bib78","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1158\/0008-5472.CAN-10-3471","article-title":"Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types","volume":"9","author":"Iliopoulos","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2016.10.009_bib79","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1074\/jbc.M114.596817","article-title":"Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer","volume":"290","author":"Shao","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.urolonc.2016.10.009_bib80","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1080\/15384101.2016.1151582","article-title":"Combining p53 stabilizers with metformin induces synergistic apoptosis through regulation of energy metabolism in castration-resistant prostate cancer","volume":"15","author":"Chen","year":"2016","journal-title":"Cell Cycle"},{"key":"10.1016\/j.urolonc.2016.10.009_bib81","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.eururo.2013.12.057","article-title":"Metformin in chemotherapy-na\u00efve castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08\/09)","volume":"66","author":"Rothermundt","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.10.009_bib82","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/j.1464-410X.2011.10555.x","article-title":"A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy","volume":"109","author":"Nobes","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2016.10.009_bib83","unstructured":"Clinicaltrials.gov. U.S. National Library of Medicine, U.S. National Institutes of Health, U.S. Department of Health and Human Services. United States; 2016 [cited August 5]. Available from: https:\/\/clinicaltrials.gov\/ct2\/results?term=prostate+cancer+metformin&Search=Search."},{"key":"10.1016\/j.urolonc.2016.10.009_bib84","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2016.10.009_bib85","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2006.05.9741","article-title":"Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy","volume":"24","author":"Braga-Basaria","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.10.009_bib86","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.10.009_bib87","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.juro.2014.12.027","article-title":"Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer","volume":"193","author":"Tsai","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.10.009_bib88","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.eururo.2012.12.004","article-title":"Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality","volume":"63","author":"Spratt","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.10.009_bib89","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1200\/JCO.2009.19.6410","article-title":"Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer","volume":"27","author":"Jiralerspong","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.10.009_bib90","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1002\/cncr.26151","article-title":"Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes","volume":"117","author":"Tan","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2016.10.009_bib91","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ijrobp.2015.06.003","article-title":"Metformin: a novel biological modifier of tumor response to radiation therapy","volume":"93","author":"Koritzinsky","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2016.10.009_bib92","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.2337\/dc11-1829","article-title":"Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients","volume":"35","author":"Lehman","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.urolonc.2016.10.009_bib93","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/pcan.2014.47","article-title":"Synergism between metformin and statins in modifying the risk of biochemical recurrence following radical prostatectomy in men with diabetes","volume":"18","author":"Danzig","year":"2015","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urolonc.2016.10.009_bib94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0022163","article-title":"Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs)","volume":"6","author":"Nies","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2016.10.009_bib95","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/pcan.2015.8","article-title":"Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08\/09)","volume":"18","author":"Joerger","year":"2015","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urolonc.2016.10.009_bib96","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1158\/2159-8290.CD-12-0263","article-title":"Investigating metformin for cancer prevention and treatment: the end of the beginning","volume":"2","author":"Pollak","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.urolonc.2016.10.009_bib97","doi-asserted-by":"crossref","first-page":"15321","DOI":"10.18632\/oncotarget.4148","article-title":"Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells","volume":"6","author":"Bansal","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2016.10.009_bib98","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1634\/theoncologist.2013-0111","article-title":"Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis","volume":"18","author":"Yin","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.urolonc.2016.10.009_bib99","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/pros.23049","article-title":"Metformin effects on biochemical recurrence and metabolic signaling in the prostate","volume":"75","author":"Winters","year":"2015","journal-title":"Prostate"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143916303167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143916303167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:09:19Z","timestamp":1761041359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143916303167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S1078143916303167"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2016.10.009","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review for clinicians: Prostate cancer and the antineoplastic properties of metformin","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2016.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}